Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeannine Thomas

Physician Assistant San Antonio, TX Physician Assistant

NPI 1962737957 CMS profile 10950884

15614 Huebner Rd, Ste 110, San Antonio, TX 78248

Open in the dashboard

General payments

$15,130

788 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeannine Thomas of San Antonio, TX is reported in the CMS Open Payments database as having received $15,130 across 788 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $836 31
2024 General $3,263 188
2023 General $3,837 202
2022 General $3,868 174
2021 General $3,326 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeannine Thomas
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jeannine Thomas were reported at $836. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jeannine Thomas Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,326 $132 $37–$438 $132
2022 $3,868 $155 $48–$522 $149
2023 $3,837 $167 $52–$557 $160
2024 $3,263 $178 $55–$600 $164
2025 $836 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,527 84 payments
  2. Novartis Pharmaceuticals Corporation $1,274 113 payments
  3. Medtronic, Inc. $1,198 23 payments
  4. Teva Pharmaceuticals USA, Inc. $948 74 payments
  5. TG Therapeutics, Inc. $877 42 payments
  6. Abbott Laboratories $799 16 payments
  7. Neurocrine Biosciences, Inc. $580 29 payments
  8. Genentech USA, Inc. $547 23 payments
  9. Biogen, Inc. $500 27 payments
  10. ACADIA Pharmaceuticals Inc $451 28 payments
  11. Other $6,429 329 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,196 777 payments
  2. Travel and Lodging $659 9 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
  4. Education $75 1 payment
Products named General payments · program years 2021–2025
  1. PERCEPT PC BRAINSENSE $1,088 18 payments
  2. BRIUMVI $877 42 payments
  3. UBRELVY $841 50 payments
  4. KESIMPTA Neurology $825 80 payments
  5. AUSTEDO $612 47 payments
  6. INGREZZA $580 29 payments
  7. OCREVUS $547 23 payments
  8. KESIMPTA Neuroscience $425 32 payments
  9. TYSABRI $386 21 payments
  10. Ongentys $385 22 payments
  11. Other $10,026 518 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

601

Median for Physician Assistant: 241

Drug cost

$238,181

Median for Physician Assistant: $4,110

Branded share of claims

17%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gilenya Fingolimod Hcl Brand 13 $137,148
Teriflunomide Generic 15 $75,288
Lacosamide Generic 18 $4,742
Dimethyl Fumarate Generic 17 $4,021
Memantine Hcl Er Memantine Hcl Brand 15 $2,396
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 27 $2,246
Sumatriptan Succinate Generic 28 $1,572
Carbamazepine Er Carbamazepine Brand 22 $1,401
Levetiracetam Generic 24 $1,194
Gabapentin Generic 34 $1,135

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$4,152

Medicare's payments for the services billed

Medicare patients

51

Average age 71

Services billed

129

32 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 47%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
  • TG Therapeutics, Inc. $474
$474 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $331
$331 — —
Leqembi
  • Eisai Inc. $140
$140 — —
QULIPTA
  • AbbVie, Inc. $137
$137 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

788 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record